BioCryst Pharmaceuticals is a Durham, North Carolina-based biotechnology firm that focuses on the development of small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its stock has a median consensus analyst price target of $18 with a high target of $23.00, and a...